Validation of the PCA3 urine test in a multicenter study in the Netherlands;Validatie van de PCA3-urinetest in een Nederlandse multicenterstudie

Nederlands Tijdschrift voor Urologie

Volumn 15, Issue 2, 2007, Pages

  Van Gils, M P M Q ^a   Hessels, D ^a   Van Hooij, O ^a   Jannink, S A ^a   Peelen, W P ^a   Hanssen, S L J ^a   Witjes, J A ^a   Cornel, E B ^b   Karthaus, H F M ^c   Smits, G A H J ^d   Dijkman, G A ^e   Mulders, P F A ^a   Schalken, J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e AMPHIA HOSPITAL   (Netherlands)

Author keywords

Diagnosis; Human; Multicenter study; Prostate cancer antigen 3; Prostatic neoplasms; Urine

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; SENSITIVITY AND SPECIFICITY; TUMOR GENE; URINALYSIS; URINE; VALIDITY;

EID: 33947278455     PISSN: 09290184     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARCPress, 2004.
3. Gils MP van, Stenman UH, Schalken JA, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 2005; 48: 1031-41.
4. Bussemakers MJ, Bokhoven A van, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9.
5. Kok JB de, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8.
6. Hessels D, Klein Gunnewiek JM, Oort I van, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15.
7. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-5.
8. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine. A new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-6.
9. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95.
10. Ylikoski A, Sjoroos M, Lundwall A, et al. Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA. Clin Chem 1999; 45: 1397-407.
11. Ylikoski A, Karp M, Lilja H, Lovgren T. Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes. Biotechniques 2001; 30: 832-6, 838, 840.
12. Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: who, how and when? A review. Eur Urol 2002; 42: 93-103.